Genomic Mismatch at Locus and Kidney Allograft Rejection.

N Engl J Med

From the Department of Medicine, Division of Nephrology (N.J.S., Y.L., J.A.D., C.F., L.L., K.X., Y.-J.N., Y.D.N., J.Y.Z., R.S., O.B., D.B., N.O., F.O., S.G., K.M., J.W., S.M., J.R., D.J.C., J.B., A.G.G., K.K.), the Department of Surgery (L.E.R.), and the Department of Pathology and Cell Biology (E.-R.M.V., G.V., V.D.), Vagelos College of Physicians and Surgeons, and the Departments of Epidemiology (S.M.) and Biostatistics (I.I.-L.), Mailman School of Public Health, Columbia University, New York; Immunogenetics and Biology of Transplantation, Città della Salute e della Scienza, University Hospital of Turin, and Medical Genetics, Department of Medical Sciences, University of Turin, Turin (Z.D., S.D., A.A.), and the Division of Nephrology, Azienda Ospedaliera Spedali Civili of Brescia, Montichiari Hospital, University of Brescia, Brescia (F.S.) - all in Italy; the Department of Pathology, M.D. Anderson Cancer Center, Houston (F.Z.J.); the Division of Genetics and Genomics, Boston Children's Hospital, and the Department of Medical Oncology, Dana-Farber Cancer Institute, Boston (M.R.); the Department of Pediatrics, Division of Pediatric Nephrology, University of Michigan School of Medicine, Ann Arbor (C.E.G., M.G.S.); the Department of Medicine, Renal, Electrolyte, and Hypertension Division, University of Pennsylvania, Philadelphia (Y.-A.K., K.S.); the Division of Nephrology, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey (Y.C.); the Nephrology Research Group, Queen's University of Belfast, Belfast, United Kingdom (A.E.C., A.P.M., A.J.M.); and the Department of Internal Medicine, Division of Nephrology (S.J.L.B., M.H.B.), and the Department of Epidemiology, Unit of Genetic Epidemiology and Bioinformatics (H.S.), University of Groningen, University Medical Center Groningen, Groningen, the Netherlands.

Published: May 2019

Background: In the context of kidney transplantation, genomic incompatibilities between donor and recipient may lead to allosensitization against new antigens. We hypothesized that recessive inheritance of gene-disrupting variants may represent a risk factor for allograft rejection.

Methods: We performed a two-stage genetic association study of kidney allograft rejection. In the first stage, we performed a recessive association screen of 50 common gene-intersecting deletion polymorphisms in a cohort of kidney transplant recipients. In the second stage, we replicated our findings in three independent cohorts of donor-recipient pairs. We defined genomic collision as a specific donor-recipient genotype combination in which a recipient who was homozygous for a gene-intersecting deletion received a transplant from a nonhomozygous donor. Identification of alloantibodies was performed with the use of protein arrays, enzyme-linked immunosorbent assays, and Western blot analyses.

Results: In the discovery cohort, which included 705 recipients, we found a significant association with allograft rejection at the locus represented by rs893403 (hazard ratio with the risk genotype vs. nonrisk genotypes, 1.84; 95% confidence interval [CI], 1.35 to 2.50; P = 9.8×10). This effect was replicated under the genomic-collision model in three independent cohorts involving a total of 2004 donor-recipient pairs (hazard ratio, 1.55; 95% CI, 1.25 to 1.93; P = 6.5×10). In the combined analysis (discovery cohort plus replication cohorts), the risk genotype was associated with a higher risk of rejection than the nonrisk genotype (hazard ratio, 1.63; 95% CI, 1.37 to 1.95; P = 4.7×10). We identified a specific antibody response against LIMS1, a kidney-expressed protein encoded within the collision locus. The response involved predominantly IgG2 and IgG3 antibody subclasses.

Conclusions: We found that the locus appeared to encode a minor histocompatibility antigen. Genomic collision at this locus was associated with rejection of the kidney allograft and with production of anti-LIMS1 IgG2 and IgG3. (Funded by the Columbia University Transplant Center and others.).

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6589355PMC
http://dx.doi.org/10.1056/NEJMoa1803731DOI Listing

Publication Analysis

Top Keywords

kidney allograft
12
allograft rejection
12
hazard ratio
12
gene-intersecting deletion
8
three independent
8
independent cohorts
8
donor-recipient pairs
8
genomic collision
8
discovery cohort
8
risk genotype
8

Similar Publications

Donor-derived cell-free DNA (dd-cfDNA) in the peripheral blood of allograft recipients has shown to early identify allograft injury. In this study, we assessed the factors that influence the amount of circulating dd-cfDNA during the first month postkidney transplant as well as its longitudinal trend. A consecutive series of 98 adult kidney transplant recipients at a single center between July 2018 and January 2020 were included in this study.

View Article and Find Full Text PDF

Gut Microbial Dysbiosis and Implications in Solid Organ Transplantation.

Biomedicines

December 2024

Department of Surgery, Duke University, Durham, NC 27710, USA.

The gut microbiome has been shown to play a significant role in solid organ transplantation, potentially influencing graft function and patient outcomes. Dysbiosis, characterized by reduced microbial diversity and an increase in pathogenic taxa, has been linked to higher incidences of allograft rejection, graft dysfunction, and post-transplant mortality. Several studies suggest that the gut microbiome might be able to serve as both a biomarker and a therapeutic target, potentially guiding personalized immunosuppressive therapies and other interventions to improve outcomes after solid organ transplantation.

View Article and Find Full Text PDF

Donor-derived cell-free DNA in chronic lung allograft dysfunction phenotypes: a pilot study.

Front Transplant

December 2024

Laboratory of Respiratory Diseases and Thoracic Surgery (BREATHE), Department of CHROMETA, KU Leuven, Leuven, Belgium.

Long-term survival after lung transplantation is limited due to chronic lung allograft dysfunction (CLAD), which encompasses two main phenotypes: bronchiolitis obliterans syndrome (BOS) and restrictive allograft syndrome (RAS). Donor-derived cell-free DNA (dd-cfDNA) is a biomarker for (sub)clinical allograft injury and could be a tool for monitoring of lung allograft health across the (pre)clinical spectrum of CLAD. In this proof-of-concept study, we therefore assessed post-transplant plasma dd-cfDNA levels in 20 CLAD patients (11 BOS and 9 RAS) at three consecutive time points free from concurrent infection or acute rejection, during stable condition, preclinical CLAD, and established CLAD ( = 3 × 20 samples).

View Article and Find Full Text PDF

Background: Proteinuria is associated with worse allograft outcomes in kidney transplant recipients (KTRs) and treatment strategies are limited. We examined the outcomes of calcineurin inhibitor (CNI) to belatacept conversion in proteinuric KTRs.

Methods: In a pilot phase II single-arm multicenter prospective trial, we recruited adult KTRs >6 months post-kidney transplantation with an estimated glomerular filtration rate (eGFR) ≥30 ml/min/1.

View Article and Find Full Text PDF

Long-term survival has improved in kidney transplant recipients (KTRs) due to effective surgical techniques and anti-rejection therapies. Chronic immunosuppression associated with it has led to several types of skin cancers leading to substantial morbidity and mortality. Structured patient education including sun protective behaviors, regular dermatological surveillance, nicotinamide, long-chain omega-3 polyunsaturated fatty acids (PUFAs), early switch to mammalian target of rapamycin inhibitors (mTORis), combining them with low-dose calcineurin inhibitors (CNIs), can decrease the cancer risk.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!